HighTower Advisors
GBT

HighTower Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

HighTower Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,219
Closed -$220K – 3521
2021
Q2 		$220K Buy
6,219
+28
+0.5% +$1.09K ﹤0.01% 2602
2021
Q1 		$250K Buy
6,191
+651
+12% +$29.9K ﹤0.01% 2429
2020
Q4 		$237K Buy
+5,540
New +$273K ﹤0.01% 2097
2020
Q1 		– Sell
-4,523
Closed -$361K – 2573
2019
Q4 		$361K Buy
+4,523
New +$268K ﹤0.01% 1602
2017
Q2 		– Sell
-20,390
Closed -$750K – 2356
2017
Q1 		$750K Sell
20,390
-100
-0.5% -$2.52K 0.01% 1160
2016
Q4 		$297K Buy
+20,490
New +$360K ﹤0.01% 1480

Other funds holding GBT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

HighTower Advisors's GBT Position: Q3 2021 in Review

HighTower Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2021, closing a stake of 6,219 shares — an estimated $220K sold.

HighTower Advisors first reported a position in GBT in Q4 2016 and held it in 6 quarters. The position peaked at $750K in Q1 2017. 187 funds tracked by Wall St. Rank hold GBT as of Q3 2021.

  • HighTower Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • HighTower Advisors sold 6,219 Global Blood Therapeutics, Inc. shares in Q3 2021, an estimated $220K.
  • HighTower Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2016 and held it in 6 quarters.
  • HighTower Advisors's Global Blood Therapeutics, Inc. position peaked at $750K in Q1 2017.
  • 187 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2021.

Based on HighTower Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.